^
    Back
    Association details:
    Biomarker:CD38 expression
    Cancer:Peripheral T-cell Lymphoma
    Drug:SAR442257 (CD3 agonist, CD38 inhibitor, CD28 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2023
    Title:

    4384 The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

    Published date:
    11/02/2023
    Excerpt:
    The SAR442257 induced efficient killing of all CD28+/CD38+ and CD28-/CD38+ PTCL lines (with maximum killing reaching about 35%)...SAR442257 can efficiently kill malignant PTCL cells, while ensuring effective T-cell activation...